Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Giant-Cell Arteritis Market Achieve During 2025–2034, and What Does It Indicate?

The market size for giant-cell arteritis has experienced significant expansion in the previous years. The market, projected to escalate from $1.07 billion in 2024 to $1.12 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. Factors contributing to the progressive growth during the historical phase include epidemiological research, genetic discoveries, rising use of biologics, enhancement in diagnostic methods, and the progression of targeted treatments and biologics.

The market size for giant-cell arteritis is projected to consistently rise in the coming years, escalating to $1.36 billion by 2029 with a compound annual growth rate (CAGR) of 5.0%. This anticipated growth can be credited to factors such as higher diagnosis rates, an aging demographic, increased funding in healthcare, advocacy by patients, and market expansion into uncharted geographic areas. Key trends anticipated in the forecast period consist of progression in pinpointing and verifying biomarkers, evolution of treatments aimed at specific molecular pathways, adoption of sophisticated imaging methods, innovations in administering medication, and the use of AI algorithms for predictive analysis.

What Drivers Are Shaping the Growth of the Giant-Cell Arteritis Market?

The rising focus on customized medical treatments is seen as a significant driver for the expansion of the giant-cell arteritis market. This personalized approach to medicine is centered around tailoring treatments to various individual factors such as genetic make-up, lifestyle habits, and environmental influences. With recent advancements in genomics, biotechnology, and data analytics, personalized medicine has been making way for the development of pinpointed therapies that not only enhance treatment effectiveness but also minimize negative side effects for patients. This approach can greatly benefit those with giant-cell arteritis (GCA) as it enables the development of targeted therapies that take into account each patient’s unique genetic traits, immune system profiles, and disease patterns. As an example, in February 2024, the Personalized Medicine Coalition (PMC), a non-profit organization in the U.S., reported that more than a third of all new drug approvals by the U.S. Food and Drug Administration (FDA) for four consecutive years were personalized medicines. In 2023, the FDA gave the green light to 16 new tailor-made treatments for rare diseases, which was a substantial jump from the six approvals in the previous year. In addition to this, the approvals that year covered seven cancer medications and three treatments for diverse diseases and ailments. Thus, the rapid surge in personalized medicine has been a strong driving force propelling the growth of the giant-cell arteritis market.

Request Your Free Giant-Cell Arteritis Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Who Are the Key Firms Paving the Way for Growth in the Giant-Cell Arteritis Market?

Major companies operating in the giant-cell arteritis market are:

• Shell Plc

• Cargill Incorporated

• Archer Daniels Midland Company

• BASF SE

• The Procter & Gamble Company

What Are the Most Influential Trends Currently Shaping the Giant-Cell Arteritis Market?

Leading businesses in the giant-cell arteritis market are innovating and releasing new products, especially biosimilars, to broaden treatment possibilities and cater to the unserved medical requirements of patients. A biosimilar refers to a biologic medicine that greatly resembles an already sanctioned biological product, exhibiting no substantial differences in terms of safety, purity, and effectiveness. For example, in April 2024, Fresenius SE & Co. KGaA, a healthcare company based in Germany, introduced Tocilizumab-aazg in the American market for the treatment of persistent autoimmune diseases. The approval of this biosimilar extends to conditions like rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The green light for this biosimilar was granted based on the outcomes of a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient groups.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

How Are Market Segments in the Giant-Cell Arteritis Industry Positioned for Long-Term Growth?

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Which Regions Are Essential for the Growth of the Giant-Cell Arteritis Market?

North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Giant-Cell Arteritis Market Defined?

Giant-cell arteritis (GCA) is a type of vasculitis, or inflammation of blood vessels, predominantly affecting medium to large arteries. It commonly involves the temporal arteries, leading to headaches, scalp tenderness, and vision problems. GCA is characterized by inflammation of the vessel walls, potentially leading to serious complications such as blindness or stroke if untreated. Treatment typically involves high-dose corticosteroids to suppress inflammation and prevent complications.

Browse Through More Similar Reports By The Business Research Company:

Cell Based Assays Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Cell Culture Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Stem Cell Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: